All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Initial results from the phase II MagnetisMM-6 study: Part 1, dose level G
Do you know... Part 1 of the MagnetisMM-6 trial has confirmed the phase III dosing regimen of elranatamab to be evaluated in combination with daratumumab and lenalidomide in part 2 of the study. What is it?
During the European Hematology Association (EHA) 2025 Congress, June 12–15, 2025, Milan, IT, Meletios A. Dimopoulos shared the initial results from the phase II MagnetisMM-6 study (NCT05623020) part 1, dose level G of elranatamab in combination with daratumumab and lenalidomide (EDR) for the treatment of transplant-ineligible newly diagnosed multiple myeloma.
Dose level G consisted of EDR administered in 28-day cycles, with subcutaneous elranatamab 76 mg every 4 weeks. The dose level G informed the recommended phase III dose of elranatamab for part 2 of MagnetisMM-6, due to its benefit–risk balance.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
HCPs, which of the following best characterizes your perception of belantamab mafodotin in combination (BVd, BPd) for the treatment of relapsed/refractory multiple myeloma?
.webp&w=3840&q=75)
.webp&w=3840&q=75)
.webp&w=3840&q=75)